News
MIST
0.7597
-3.79%
-0.0299
Milestone Pharmaceuticals Inc. Receives Nasdaq Notice of Non-Compliance Under Rule 5450(a)(1)
NASDAQ · 1d ago
Milestone Pharmaceuticals Faces Nasdaq Listing Compliance Challenge
TipRanks · 1d ago
Weekly Report: what happened at MIST last week (1019-1023)?
Weekly Report · 4d ago
Milestone Pharmaceuticals price target lowered to $5 from $6 at Raymond James
TipRanks · 10/20 13:01
Weekly Report: what happened at MIST last week (1012-1016)?
Weekly Report · 10/19 09:11
Weekly Report: what happened at MIST last week (1005-1009)?
Weekly Report · 10/12 09:12
Sagimet Reports Sustained Acne Improvements With Denifanstat Through 52 Weeks
NASDAQ · 10/09 13:39
Milestone Moves Etripamil AFib-RVR Program Forward With First European Patient; Stock Up
NASDAQ · 10/09 13:19
Milestone Pharmaceuticals enrolls first European patient in ReVeRA-301 trial
TipRanks · 10/09 12:10
Milestone Pharmaceuticals management to meet virtually with Cantor
TipRanks · 10/08 20:55
Weekly Report: what happened at MIST last week (0928-1002)?
Weekly Report · 10/05 09:12
Weekly Report: what happened at MIST last week (0921-0925)?
Weekly Report · 09/28 09:12
Milestone Enrolls First Canadian Patient In Phase 3 For Etripamil
NASDAQ · 09/27 12:28
Milestone announces Montreal Heart Institute enrolled first patient
TipRanks · 09/24 12:11
Analysts Offer Insights on Healthcare Companies: Marker Therapeutics (MRKR), Milestone Pharmaceuticals (MIST) and Pfizer (PFE)
TipRanks · 09/22 10:20
Weekly Report: what happened at MIST last week (0914-0918)?
Weekly Report · 09/21 09:12
Weekly Report: what happened at MIST last week (0907-0911)?
Weekly Report · 09/14 09:12
Weekly Report: what happened at MIST last week (0831-0904)?
Weekly Report · 09/07 09:11
Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals
NASDAQ · 09/04 14:09
Milestone Wins China Approval for Etripamil Nasal Spray
TipRanks · 09/03 22:52
More
Webull provides a variety of real-time MIST stock news. You can receive the latest news about Milestone Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About MIST
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.